Synthesis and Pharmacological Evaluation of 6,7-Dihydro‑3H‑Oxazolo[3,4‑a]Pyrazine-5,8-Dione Compounds as Inhibitors of Phosphodiesterases 4 and 5
Abstract
Benign prostatic hyperplasia (BPH) is a prevalent condition in aging men that negatively affects the quality of life. Current therapeutic strategies aim to reduce prostate size and smooth muscle contraction. In this study, five novel 4-oxazoline-centered compounds with potential phosphodiesterase (PDE) inhibitory activity were synthesized and tested for biochemical and pharmacological effects in isolated prostate cells and tissues. Among them, compound VIII exhibited inhibitory activity against PDE5 and two PDE4 isoforms in cell-free assays. Additionally, it relaxed isolated rat prostate tissue, enhanced nitric oxide-induced relaxation, and reduced contractile responses mediated by alpha-1 adrenoceptors. Moreover, compound VIII significantly inhibited the proliferation of a human hyperplastic prostate cell line, mimicking the effects of rolipram, a PDE4 inhibitor. With its dual inhibition of PDE4 and PDE5 and its ability to decrease both contraction and cell proliferation, compound VIII emerges as a promising candidate for further investigation as a potential treatment for BPH. Complementary molecular docking and conformational analyses provided a structural rationale for the observed activity trends, highlighting the role of hydroxyethyl substituent interactions with the PDE5A H-loop in modulating inhibitory potency. Taken together, the dual PDE4/PDE5 inhibition profile of compound VIII, combined with its favorable functional effects on smooth muscle tone and cell…
Read the paper
Related studies
- Treatment of non-metastatic castration-resistant prostate cancer: facing age-related comorbidities and drug–drug interactions
- The Efficacy of Flogofilm® in the Treatment of Chronic Bacterial Prostatitis as an Adjuvant to Antibiotic Therapy: A Randomized Prospective Trial
- Inhibition of growth and contraction in human prostate stromal cells by silencing of NUAK1 and -2, and by the presumed NUAK inhibitors HTH01-015 and WZ4003
- Effectiveness and Safety of a New Nutrient Fixed Combination Containing Pollen Extract Plus Teupolioside, in the Management of LUTS in Patients with Benign Prostatic Hypertrophy: A Pilot Study
- Extract from Cucurbita pepo improves BPH symptoms without affecting sexual function: a 24-month noninterventional study
- Aquablation vs. holmium laser enucleation of the prostate for benign prostatic hyperplasia: a 150-patients prospective comparative multicenter study
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.